Business Context and Reporting Period
This Form 8-K is filed by Onconova Therapeutics, Inc. (ONTX) on July 26, 2019. The filing addresses a notice of delisting or failure to satisfy a continued listing rule regarding the company's status on The Nasdaq Capital Market.
Key Financial Metrics
The filing references the company's financial position as of March 31, 2019, based on the Quarterly Report on Form 10-Q.
- Stockholders' Equity: Approximately $1.5 million deficit.
- Nasdaq Minimum Requirement: $2.5 million in stockholders' equity.
- Compliance Status: The company failed to meet the minimum equity requirement and did not meet alternative criteria regarding market value of listed securities or net income from continuing operations.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity beyond the stockholders' deficit figure.
Material Changes and Regulatory Status
On May 21, 2019, Nasdaq notified the company of non-compliance with Listing Rule 5550(b) due to the stockholders' deficit. The company was granted 45 days to submit a compliance plan. On July 26, 2019, Nasdaq accepted the company's plan to regain compliance within 180 days of the initial notification.
Outlook, Risks, and Contingencies
Compliance Deadline: The company must regain compliance with Nasdaq Listing Rule 5550(b) by November 18, 2019.
Delisting Risk: If the company fails to regain compliance by the deadline or fails to satisfy other listing requirements, Nasdaq staff may issue a notice that the common shares will be subject to delisting.
Appeal Process: In the event of a delisting determination, the company may appeal to a Nasdaq Hearings Panel. Management states there can be no guarantee that the company will be able to maintain its Nasdaq listing.
Investor Verification Checklist
- Verify the company's progress toward regaining compliance with Nasdaq Listing Rule 5550(b) by the November 18, 2019 deadline.
- Review the most recent Form 10-Q or 10-K to confirm the current stockholders' equity position and cash runway.
- Monitor for any subsequent 8-K filings regarding delisting notices or appeals to the Nasdaq Hearings Panel.
- Confirm whether the company has executed capital raising activities to address the equity deficit.